| pubmed-article:3042050 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3042050 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:3042050 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:3042050 | lifeskim:mentions | umls-concept:C0218633 | lld:lifeskim |
| pubmed-article:3042050 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:3042050 | lifeskim:mentions | umls-concept:C1518071 | lld:lifeskim |
| pubmed-article:3042050 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3042050 | pubmed:dateCreated | 1988-9-21 | lld:pubmed |
| pubmed-article:3042050 | pubmed:abstractText | The use of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) following autologous marrow transplantation for lymphoid malignancies was explored in a phase I/II dose escalation study. rhGM-CSF given as a 2-hour infusion daily for 14 days was well tolerated at doses up to 240 micrograms/m2/day. When compared with 86 disease-matched and treatment-matched historical controls, patients receiving greater than or equal to 60 micrograms/m2/day rhGM-CSF recovered neutrophil and platelet counts more rapidly, had fewer days with fever, and were discharged from the hospital sooner. | lld:pubmed |
| pubmed-article:3042050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3042050 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3042050 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3042050 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3042050 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3042050 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:StorbRR | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:ThomasE DED | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:BucknerC DCD | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:HillRR | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:SingerJ WJW | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:AppelbaumF... | lld:pubmed |
| pubmed-article:3042050 | pubmed:author | pubmed-author:NemunaitisJJ | lld:pubmed |
| pubmed-article:3042050 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3042050 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:3042050 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3042050 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3042050 | pubmed:pagination | 834-6 | lld:pubmed |
| pubmed-article:3042050 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:meshHeading | pubmed-meshheading:3042050-... | lld:pubmed |
| pubmed-article:3042050 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3042050 | pubmed:articleTitle | Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. | lld:pubmed |
| pubmed-article:3042050 | pubmed:affiliation | Fred Hutchinson Cancer Research Center, Seattle, WA. | lld:pubmed |
| pubmed-article:3042050 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3042050 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3042050 | lld:pubmed |
